HEPAOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as CTRVP
Hepion Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.10−0.00 (-1.45%)
Close on Oct 19, 2026
- Market cap
- $1.65M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Hepion Pharmaceuticals's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
11 buys · 0 sales
Net bought $1.23M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Anson Funds Management LP | 595,719 | 9.90% | 13G (passive) | Mar 31, 2025 |
| Kenneth Rickel | 5,250,000 | 5.70% | 13G (passive) | Aug 3, 2026 |
| Gary Stetz | 5,250,000 | 5.70% | 13D (active) | Aug 3, 2026 |
| Sireesh Appajosyula | 5,250,000 | 5.70% | 13D (active) | Aug 3, 2026 |
| Vincent LoPriore | 26,250,000 | 26.20% | 13D (active) amendment | Aug 3, 2026 |
| Bigger Capital Fund GP, LLC | 1,060,883 | 9.99% | 13G (passive) | Jan 21, 2025 |
| KI Holdings Ltd. | 10,000,000 | 10.20% | 13D (active) amendment | Aug 3, 2026 |
| Black Global 5 LLC | 10,000,000 | 11.10% | 13D (active) | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Vincent S. LoPriore | Executive Chairman, Director | 30,500,000 | Sep 14, 2026 |
| Gary S. Stetz | Interim CEO, Director | 4,500,000 | Aug 21, 2026 |
| Chase LoPriore | VP, Corp. Dev., Director | 1,250,000 | Aug 21, 2026 |
| Sireesh Appajosyula | Chief Operating Officer, Director | 3,250,000 | Aug 21, 2026 |
| Michael J. Purcell | Director | 3,250,000 | Sep 10, 2026 |
| James Gordon Liddy | Director | – | Aug 21, 2026 |
| Danina Fisher | Director | – | Aug 21, 2026 |
| Gary S. Stetz II | Director | 500,000 | Aug 21, 2026 |
| KI Holdings, Ltd. | 10% owner | 10,000,000 | Sep 16, 2026 |
| Global 5 LLC Black | 10% owner | 10,000,000 | Aug 7, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael J. Purcell Director | Aug 3, 2026 | Buy | +2,000,000 | $0.05 | $100.00K | 3,250,000 |
| Gary S. Stetz Interim CEO, Director | Aug 3, 2026 | Buy | +2,000,000 | $0.05 | $100.00K | 3,250,000 |
| Sireesh Appajosyula Chief Operating Officer, Director | Aug 3, 2026 | Buy | +2,000,000 | $0.05 | $100.00K | 3,250,000 |
| Vincent S. LoPriore Executive Chairman, Director | Aug 3, 2026 | Buy | +8,000,000 | $0.05 | $400.00K | 14,250,000 |
| Vincent S. LoPriore Executive Chairman, Director | Aug 3, 2026 | Buy | +2,000,000 | $0.05 | $100.00K | 16,250,000 |
| Gary S. Stetz II Director | Aug 3, 2026 | Buy | +500,000 | $0.05 | $25.00K | 500,000 |
| Michael J. Purcell Director | Apr 21, 2026 | Buy | +1,250,000 | $0.04 | $50.00K | 1,250,000 |
| Gary S. Stetz Interim CEO, Director | Apr 21, 2026 | Buy | +1,250,000 | $0.04 | $50.00K | 1,250,000 |
| Sireesh Appajosyula Director | Apr 21, 2026 | Buy | +1,250,000 | $0.04 | $50.00K | 1,250,000 |
| Vincent S. LoPriore Executive Chairman, Director, 10% owner | Apr 21, 2026 | Buy | +5,000,000 | $0.04 | $200.00K | 5,000,000 |
| Vincent S. LoPriore Executive Chairman, Director, 10% owner | Apr 21, 2026 | Buy | +1,250,000 | $0.04 | $50.00K | 6,250,000 |
| Peter Wijngaard Director | Nov 27, 2023 | Buy | +2,500 | $3.05 | $7.63K | 9,501 |
| Peter Wijngaard Director | Nov 24, 2023 | Buy | +2,500 | $3.09 | $7.73K | 7,001 |
| Peter Wijngaard Director | Sep 19, 2023 | Buy | +1,000 | $5.64 | $5.64K | 4,501 |
| Robert T. Foster CEO and Director | Sep 18, 2023 | Buy | +1,600 | $5.60 | $8.96K | 50,470 |
| Peter Wijngaard Director | Sep 15, 2023 | Buy | +1,000 | $5.82 | $5.82K | 2,501 |
| Peter Wijngaard Director | Sep 15, 2023 | Buy | +139 | $5.45 | $758 | 2,640 |
| Peter Wijngaard Director | Sep 15, 2023 | Buy | +861 | $5.37 | $4.62K | 3,501 |
| Robert T. Foster CEO,CSO and Director | Sep 15, 2023 | Buy | +1,600 | $5.40 | $8.64K | 48,870 |
| John T. Cavan Chief Financial Officer | Feb 18, 2021 | Buy | +10,000 | $2.00 | $20.00K | 14,800 |
| Robert T. Foster CEO and Director | Feb 18, 2021 | Buy | +20,000 | $2.00 | $40.00K | 45,259 |
| Peter Wijngaard Director | Feb 16, 2021 | Buy | +10,000 | $2.20 | $22.00K | 30,000 |
| Peter Wijngaard Director | Dec 18, 2020 | Buy | +20,000 | $1.91 | $38.20K | 20,000 |
| Robert T. Foster CEO and Director | Dec 8, 2020 | Buy | +25,000 | $1.58 | $39.50K | 25,259 |
| John P. Brancaccio Director | Dec 2, 2020 | Buy | +7,000 | $1.53 | $10.71K | 7,008 |
| Gary S. Jacob Director | Dec 1, 2020 | Buy | +12,000 | $1.66 | $19.92K | 12,059 |
| John T. Cavan Chief Financial Officer | Nov 25, 2020 | Buy | +4,500 | $1.62 | $7.29K | 4,800 |
| John T. Cavan CFO | Jan 3, 2018 | Award | +101,221 | – | – | 167,947 |
| Robert T. Foster Chief Scientific Officer | Jan 3, 2018 | Award | +100,654 | – | – | 144,736 |
| James Sapirstein Chief Executive Officer, Director | Jan 3, 2018 | Award | +322,092 | – | – | 492,819 |
| Robert T. Foster Chief Scientific Officer | Jul 6, 2017 | Award | +44,082 | – | – | 44,082 |
| John Z. Sullivan-Bolyai Chief Medical Officer | Jul 6, 2017 | Award | +58,681 | – | – | 58,681 |
| James Sapirstein Chief Executive Officer, Director | Jul 6, 2017 | Award | +141,061 | – | – | 170,727 |
| John T. Cavan CFO | Jul 6, 2017 | Award | +46,726 | – | – | 66,726 |
| John T. Cavan CFO | Jun 20, 2017 | Buy | +20,000 | $0.65 | $13.00K | 20,000 |
| James Sapirstein Chief Executive Officer, Director | Oct 27, 2016 | Option exercise | +16,666 | $1.50 | $25.00K | 29,666 |
| James Sapirstein Chief Executive Officer, Director | Feb 18, 2016 | Buy | +10,000 | $1.00 | $10.00K | 13,000 |
| James Sapirstein Chief Executive Officer, Director | Nov 30, 2015 | Buy | +500 | $2.15 | $1.08K | 3,000 |
| James Sapirstein Chief Executive Officer, Director | Nov 23, 2015 | Buy | +2,500 | $1.64 | $4.10K | 2,500 |
| John P. Brancaccio Director | Mar 4, 2014 | Buy | +4,393 | $1.49 | $6.55K | 6,408 |
| Bernard Denoyer Chief Financial Officer | Feb 18, 2014 | Other | +1,030 | – | – | 1,030 |
| Synergy Pharmaceuticals, Inc. 10% owner | Feb 18, 2014 | Other | −9,000,000 | – | – | 0 |
| Gary S. Jacob CEO and President, Director | Feb 18, 2014 | Other | +32,935 | – | – | 32,935 |
| John P. Brancaccio Director | Feb 18, 2014 | Other | +2,015 | – | – | 2,015 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.